|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
University of Montreal Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine Institut Universitaire de Gériatrie de Montréal Hôpital du Sacré-Coeur de Montréal Eli Lilly and Company |
|---|---|
| Information provided by: | University of Montreal |
| ClinicalTrials.gov Identifier: | NCT00290121 |
Purpose
The purpose of this study is to understand, with the use of functional magnetic resonance imaging, the neural correlates involved in appetite control and the mechanism of weight gain in patients with schizophrenia treated with atypical antipsychotics. We hypothesize that a difference in cerebral activations between weight gaining and non-weight gaining patients will be detected after four months of treatment with olanzapine.
| Condition | Intervention | Phase |
|---|---|---|
|
Schizophrenia |
Drug: Olanzapine |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Prevention, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
| Official Title: | Cerebral Mechanism Involved in Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics (IIT) |
| Estimated Enrollment: | 30 |
| Study Start Date: | September 2005 |
Atypical antipsychotics (AAP) have revolutionize treatment of schizophrenia. They are considered to be more effective in reducing positive and negative symptoms and in improving cognitive deficits. They cause less extrapyramidal symptoms and tardive dyskinesia than typical antipsychotics. They still have a lot of important side effects like sedation, metabolic syndrome and weight gain. These effects could lead to obesity, type II diabetes and cardiovascular diseases, particularly for schizophrenia patients because they are already at an increased risk for these complications. Moreover, an increase in weight gain has been demonstrate to exacerbate negative symptoms and can lead to non compliance with a consequent risk of relapse. It also can create an additional social disadvantage for schizophrenia patients and decrease their quality of life. The weight gain will result, in part from an increased food intake (and probably an increased appetite) and from a decreased energy expenditure.
The purpose of this study is to understand the cerebral mechanisms of appetite in patients with schizophrenia treated with atypical antipsychotics to prevent or treat their weight gain.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Emmanuel Stip, MD, M.Sc | 514-251-4015 ext 3396 | emmanuel.stip@umontreal.ca |
| Canada, Quebec | |
| Centre de recherche Fernand-Seguin | Recruiting |
| Montréal, Quebec, Canada, H1N 3V2 | |
| Principal Investigator: Emmanuel Stip, MD, M.Sc | |
| Principal Investigator: | Emmanuel Stip, MD, M.Sc. | Centre de recherche Fernand-Seguin, Université de Montréal |
More Information
| Study ID Numbers: | 2005-0503 |
| Study First Received: | February 8, 2006 |
| Last Updated: | February 8, 2006 |
| ClinicalTrials.gov Identifier: | NCT00290121 |
| Health Authority: | Canada: Santé Canada |
|
Schizophrenia Atypical antipsychotics Weight gain Appetite fMRI |
|
Schizophrenia Body Weight Mental Disorders Olanzapine |
Psychotic Disorders Weight Gain Serotonin Schizophrenia and Disorders with Psychotic Features |
|
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Gastrointestinal Agents Psychotropic Drugs Antiemetics Central Nervous System Depressants |
Antipsychotic Agents Serotonin Uptake Inhibitors Pharmacologic Actions Serotonin Agents Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Central Nervous System Agents |
